Healthcare Contract Manufacturing Market- Report and Size, share and Demand by 2023
Market Scenario:
The Global Healthcare Contract Manufacturing Market is expected to register 9.86% CAGR and is projected to reach USD 250.9 Billion by 2023. Contract manufacturing refers to a manufacturer who signs a contract with another company to make and provide individual components or products over a mutually agreed period. The healthcare contract manufacturing organization serves other companies in the medical devices and pharmaceutical industries to provide comprehensive services from drug development to drug manufacturing.
Some of the major drivers for the growth of healthcare contract manufacturing market across the globe are patent expiration of major drugs and medical devices, competition and economics of production and trade to favor contract manufacturing organization (CMO), mutual benefits to contract manufacturer and client, and lean manufacturing and agility. On the flip side, supply chain complexity and issues of control of third parties and standardization and interoperability issues are anticipated to hinder the market growth over the forecast period.
Regional Analysis:
Global healthcare contract manufacturings consist of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas holds the largest share of the global healthcare contract manufacturing market owing to the rising number of drug approvals as one of the factors fuelling the growth. The patent expiries of blockbuster drugs are creating a new opportunity to vendors to develop biosimilars at low cost. Thus, the market is anticipated entry of biosimilars and generics, which is likely to further strengthen the growth in this region.
The European market dominated the global healthcare contract manufacturings market owing to the high prevalence rate of various disease in the Eastern European regions.
The Asia Pacific region is anticipated to be the fastest growing region over the forecast period owing to the increasingly favorable government initiatives along with the improving healthcare infrastructure.
Access Report Details @ https://www.marketresearchfuture.com/reports/healthcare-contract-manufacturing-market-5637
Segmentation
The global healthcare contract manufacturing market is segmented on the basis of product, industry, type, and services.
On the basis of the product, the global healthcare contract manufacturing market is segmented into active pharmaceutical ingredients (API), final dosage formulations (FDF), advanced drug delivery products, OTC medicines and nutritional products, and others. Moreover, the finished dosage formulations (FDF) is segmented into a tablet, capsules, oral liquids, parenteral/injectables, and others.
On the basis of the industry, the global healthcare contract manufacturing market is segmented into pharmaceutical, biopharmaceutical, and others.
On the basis of the type, the global healthcare contract manufacturing market is segmented into sterile, non-sterile, and others
On the basis of the service, the global healthcare contract manufacturing market is segmented into oncology research, vaccines research, inflammation & immunology research, cardiology research, neuroscience research, and others.
Key Players
Some of key the players in the global healthcare contract manufacturings market are Patheon (Netherlands), Lonza (Switzerland), Evonik Industries (Germany), Teva Pharmaceutical Industries (Israel), Boehringer Ingelheim BioXcellence (Germany), Famar S.A. (Greece), Fareva Group (France), Vetter Pharma International (Germany), Mylan (U.S.), Recipharm (Sweden), Aesica Pharmaceuticals (U.K.), Althea Technologies (U.S.), Aenova (Germany), Dishman Pharmaceuticals and Chemicals Limited (India), Catalent Pharma Solutions (U.S.), Kemwell Pvt. Ltd. (India), Jubilant Life Sciences Limited (India), Nipro Corporation (Japan), NextPharma (UK), Pfizer Central Source (U.S.), Royal DSM N.V. (Netherlands), Abbott Laboratories (U.S.), Amgen (U.S.), Apotex (U.S.), Aspen (U.S.), AstraZeneca PLC (UK), Aurobindo Pharma (India), Baxter International (U.S.), BERLIN-CHEMIE (Germany), Biocon (India), Biogen (U.S.), Celltrion (South Korea), Cipla (India), Coherus Biosciences (U.S.), Daiichi Sankyo (Japan), Dr. Reddy's Laboratories (India), Eli Lilly and Company (U.S.), Emcure Pharmaceuticals (India), Eurofarma Laboratories (Brazil), Gedeon Richter (Hungary), Gilead Sciences (U.S.), GlaxoSmithKline (GSK) Plc (U.S.), Hospira (U.S.), Impax Laboratories (U.S.), Intas Pharmaceuticals (India), Janssen Pharmaceuticals (U.S.), Lupin (India), Merck and Co. Inc. (U.S.), Mitsubishi Tanabe Pharma (Japan), Momenta Pharmaceuticals (U.S.), Natco Pharma (India), Nexus Pharmaceuticals (U.S.), Novo Nordisk (Denmark), Orchid Chemicals & Pharmaceuticals (India), Par Pharmaceutical (U.S.), Parenteral Drugs (India), Piramal (India), Roche Holding (Switerzland), Sanofi (France), Synthon (Netherlands), Teva Pharmaceuticals (Israel), Valeant Pharmaceuticals (Canada), Zentiva (Czech Republic), Zhejiang Huahai Pharmaceutical (China), Zydus Cadila (India), and others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
